Entera Bio reports encouraging data from osteoporosis trial
Entera Bio Ltd. (ENTX) announced interim data from its Phase 2 clinical trial of EB613. The trial is looking to establish the potential of this drug candidate in treating osteoporosis patients. EB613 is an orally delivered human parathyroid hormone and aims to be the first oral bone-building product.
The 6-month data showed that EB613 was able to generate a mean placebo adjusted increase in lumbar spine BMD of 2.15 percent for the 14 patients included in the 1.5 mg treatment arm. 16 patients in the